Eisai

News

BMS hands back rights to cancer ADC licensed from Eisai

Bristol-Myers Squibb has ended a $3.1 billion strategic collaboration with Eisai focusing on antibody-drug conjugates (ADCs) and returned rights to the lead drug in the alliance.

News

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busti

News

Eisai, Biogen start delayed subcutaneous Leqembi filing

Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the

News

Leqembi maintenance dose filed in US, but SC form delayed

Eisai has filed to extend the label for its Alzheimer’s disease therapy Leqembi to include a maintenance dosing regimen that would reduce the number of intravenous infusio

News

Eisai and Biogen facing delay to Leqembi in Europe

Around 14 months after Eisai and Biogen’s Leqembi was filed for approval in the EU, the bloc’s regulatory authority has delayed making a decision on the Alzheimer’s drug.

News

Eisai backs Leqembi’s Japan rollout with insurance policy

A partnership between Eisai and Lifenet that aims to improve insurance cover for people with early dementia has generated its first policy, part of an effort by the pharma

BMS hands back rights to cancer ADC licensed from Eisai

Lilly’s Alzheimer’s drug set to join Leqembi after FDA vote

Eisai, Biogen start delayed subcutaneous Leqembi filing

Leqembi maintenance dose filed in US, but SC form delayed

Eisai and Biogen facing delay to Leqembi in Europe

Eisai backs Leqembi’s Japan rollout with insurance policy

FDA points to liver injury with Amgen's Tavneos

Using AI-driven synthetic personas to take your insights fur...

Eisai

Editor's Picks